Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 30;18(5):2086774.
doi: 10.1080/21645515.2022.2086774. Epub 2022 Jun 8.

Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China

Zhiying Yin  1   2 , Tingcui Wen  2 , Quanjun Fang  1 , Canjie Zheng  1 , Xiaoying Gong  1 , Junji Li  1 , Shuangqing Wang  1 , Ziling Xiang  1
Affiliations

Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China

Zhiying Yin et al. Hum Vaccin Immunother. .

Abstract

Mumps cases were reported frequently when a routine dose measles-mumps-rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006-2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated.

Keywords: Mumps; mumps-containing vaccine; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
The incidence after immunization in vaccinated children during 2006 to 2020 in Quzhou.
Figure 2.
Figure 2.
The VEs after immunization for one or two doses group during 2006 to 2020 in Quzhou.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Grennan D. Mumps. Jama. 2019;322:1. doi:10.1001/jama.2019.10982. - DOI - PubMed
    1. Moghe CS, Goel P, Singh J, Nayak NR, Dhuria M, Jain R, Yadav R, Saroha E, Sodha SV, Aggarwal CS, et al. Mumps outbreak investigation in Jaisalmer, Rajasthan, India, June-r̥september 2016. J Med Virol. 2019;91:347–6. doi:10.1002/jmv.25324. - DOI - PMC - PubMed
    1. Marx GE, Burakoff A, Barnes M, Hite D, Metz A, Miller K, Davizon ES, Chase J, McDonald C, McClean M, et al. Mumps outbreak in a Marshallese community — Denver metropolitan area, Colorado, 2016–2017. MMWR Morb Mortal Wkly Rep. 2018;67:1143–1146. doi:10.15585/mmwr.mm6741a2. - DOI - PMC - PubMed
    1. Lewnard JA, Grad YH. Vaccine waning and mumps re-emergence in the United States. Sci Transl Med. 2018;10. doi:10.1126/scitranslmed.aao5945. - DOI - PMC - PubMed
    1. Westphal DW, Eastwood A, Levy A, Davies J, Huppatz C, Gilles M, Lyttle H, Williams SA, Dowse GK. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect Dis. 2019;19:177–184. doi:10.1016/S1473-3099(18)30498-5. - DOI - PubMed

Publication types

Substances